ONC 392

Drug Profile

ONC 392

Alternative Names: ONC-392

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator OncoImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 15 Sep 2016 Pfizer enters into option agreement with OncoImmune for development and commercialisation of ONC 392
  • 29 Mar 2016 Preclinical trials in Cancer in USA (unspecified route) prior to March 2016 (Oncoimmune pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top